ID   HCA46 R2 Cetux
AC   CVCL_A2BZ
SY   HCA-46 R2 Cetux
DR   Cosmic; 2841365
DR   Wikidata; Q105507572
RX   PubMed=25623215;
CC   Selected for resistance to: DrugBank; DB00002; Cetuximab (Erbitux).
CC   Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ala183Ser (c.547G>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val272Alafs*33 (c.815_816delTG); Zygosity=Unspecified (from parent cell line).
CC   Derived from site: In situ; Colon, sigmoid; UBERON=UBERON_0001159.
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2468 ! HCA46
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 12-01-21; Last updated: 02-05-24; Version: 5
//
RX   PubMed=25623215; DOI=10.1158/1078-0432.CCR-14-2821;
RA   Arena S., Bellosillo B., Siravegna G., Martinez A., Canadas I.,
RA   Lazzari L., Ferruz N., Russo M., Misale S., Gonzalez I., Iglesias M.,
RA   Gavilan E., Corti G., Hobor S., Crisafulli G., Salido M., Sanchez J.,
RA   Dalmases A., Bellmunt J., De Fabritiis G., Rovira A.,
RA   Di Nicolantonio F., Albanell J., Bardelli A., Montagut C.;
RT   "Emergence of multiple EGFR extracellular mutations during cetuximab
RT   treatment in colorectal cancer.";
RL   Clin. Cancer Res. 21:2157-2166(2015).
//